Scott Blumberg, Chief Financial Officer of Ceribell Inc., sold 1,521 shares of the company on August 21, 2026, for $36,534 at $24.02 per share. The disposal was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
Ceribell’s stock has gained 109% over the past year and is trading near its 52-week high of $25.33. The company reported second-quarter revenue of $28.1 million for fiscal 2026, a 33% increase from the prior year, though it posted a loss of $0.51 per share, wider than the $0.36 loss forecast by analysts.
Ceribell specializes in seizure-detection technology, including point-of-care rapid EEG systems, and is developing additional products for delirium monitoring and pediatric care. Analysts have adjusted price targets upward: Canaccord raised its target to $26 from $25 while maintaining a Buy rating, and BTIG increased its target to $30 from $28.
Blumberg retains direct ownership of 146,600 shares following the transaction.
